Celgene will launch a new research incubator

| By | Celgene, Drug Development, R&D

Celgene Corporation announced its plans to open the Thomas O. Daniel Research Incubator and Collaboration Center, offering entrepreneurs state-of-the-art lab space, resources and support to scientists and companies with potentially transformational approaches to accelerate medical discoveries and innovations.

The incubator will house shared and fully equipped lab facilities located on the Celgene Summit West Research campus in Summit, New Jersey (USA) to create an environment that can help medical innovators accelerate discoveries that may lead to life-enhancing medicines for patients in need. The Incubator, set to open this year, is dedicated to Thomas O. Daniel, M.D., who served as Executive Vice President and President of Research and Early Development at Celgene from 2006 to 2016.

New Jersey hosts a multitude of biopharmaceutical leaders that are committed to medical innovations, with strong manufacturing capabilities. The state is home to a majority of the world’s top 20 research-based biopharmaceutical companies and over 3,000 life sciences establishments.

“When it comes to the challenges we face in healthcare, the facts are clear and compelling that medical innovation is the solution, not the problem. That is why Celgene is excited to offer an innovative environment for promising scientists and start-up companies to cultivate their ideas and medical discoveries,” said Robert J. Hugin, Executive Chairman of Celgene. “Hosting the incubator at Celgene aligns with our mission to pursue bold science and provide potentially transformational treatments that will ultimately benefit patients, healthcare and society.”